bioMerieux (OTCMKTS:BMXMF) Sets New 52-Week Low – Should You Sell?

bioMerieux (OTCMKTS:BMXMF – Get Free Report) hit a new 52-week low on Friday . The stock traded as low as $77.32 and last traded at $77.32, with a volume of 15 shares changing hands. The stock had previously closed at $84.21.

Wall Street Analysts Forecast Growth

BMXMF has been the subject of several research reports. Zacks Research raised bioMerieux to a “hold” rating in a report on Tuesday, April 28th. UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Piper Sandler initiated coverage on bioMerieux in a report on Thursday. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft lowered bioMerieux from a “buy” rating to a “hold” rating in a report on Friday, April 24th. Five equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, bioMerieux has an average rating of “Hold”.

Get bioMerieux alerts:

Check Out Our Latest Analysis on BMXMF

bioMerieux Price Performance

The stock has a fifty day moving average price of $91.37 and a 200 day moving average price of $109.65. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

(Get Free Report)

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.

Read More

• Five stocks we like better than bioMerieux
• ERock IPO: A $1.3B Power Play Solution
• The AI Boom Has a Hidden Winner—And It’s Not Nvidia
• SMX: Can Molecular Tracking Technology Become the Next Moonshot?
• Boeing’s Unseen Rebound: Why the Headlines Are Wrong

Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.